Romiplostim as a transfusion saving strategy in 20 patients after heart or lung transplantation: a single centre before-after pilot study.

CONCLUSION: Romiplostim did not significantly reduce platelet transfusion after heart or lung transplantation. Its relevance and safety in a global transfusion strategy remains to be studied in this setting in a large randomised study. PMID: 31359829 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31359829?dopt=Abstract

Source: Perfusion - July 29, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Vourc'h M, Senage T, Lepoivre T, Volteau C, Fortuit C, Pattier S, Guimbretiere G, Roussel JC, Rozec B Tags: Perfusion Source Type: research